Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
603392.SS Stock Summary
Top 10 Correlated ETFs
603392.SS
In the News
603392.SS Financial details
Company Rating
Buy
Market Cap
94.8B
Income
2.6B
Revenue
7.5B
Book val./share
10.62
Cash/share
4.56
Dividend
1
Dividend %
1.3%
Employees
4.02K
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
23.75
Forward P/E
12.79
PEG
2.38
P/S
12.11
P/B
4.64
P/C
15.23
P/FCF
38.06
Quick Ratio
3.53
Current Ratio
3.99
Debt / Equity
0.02
LT Debt / Equity
0.01
-
-
EPS (TTM)
3.27
EPS next Y
5.43
EPS next Q
-
EPS this Y
223.78%
EPS next Y
65.72%
EPS next 5Y
65.72%
EPS last 5Y
81.45%
Revenue last 5Y
62.65%
Revenue Q/Q
-36.94%
EPS Q/Q
-83.61%
-
-
-
-
SMA20
4.35%
SMA50
-7.69%
SMA100
67.44%
Inst Own
-
Inst Trans
-
ROA
16%
ROE
20%
ROC
0.21%
Gross Margin
89%
Oper. Margin
39%
Profit Margin
35%
Payout
35%
Shs Outstand
1.26B
Shs Float
222.93M
-
-
-
-
Target Price
-
52W Range
40.14-88.0
52W High
-21.09%
52W Low
+73.6%
RSI
47
Rel Volume
0.36
Avg Volume
16.33M
Volume
5.93M
Perf Week
-4.81%
Perf Month
12.97%
Perf Quarter
-
Perf Half Y
43.71%
-
-
-
-
Beta
2.169
-
-
Volatility
2.45%, 4.29%
Prev Close
1.98%
Price
69.44
Change
-2.17%
603392.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.92 | 1.08 | 1.97 | 4.67 | 12.54 | |
Net income per share | 0.27 | 0.19 | 0.57 | 1.64 | 5.31 | |
Operating cash flow per share | 0.2 | 0.25 | 0.39 | 1.37 | 4.63 | |
Free cash flow per share | -0.04 | 0.1 | 0.07 | 0.52 | 3.59 | |
Cash per share | 0.4 | 0.31 | 0.64 | 1.18 | 8.07 | |
Book value per share | 1.26 | 1.42 | 2.14 | 3.63 | 13.84 | |
Tangible book value per share | 1.05 | 1.22 | 1.96 | 3.47 | 13.72 | |
Share holders equity per share | 1.26 | 1.42 | 2.14 | 3.63 | 13.84 | |
Interest debt per share | 0.03 | -0.09 | 0.08 | 0.24 | 0.32 | |
Market cap | 4.73B | 4.87B | 84.74B | 134.25B | 80.71B | |
Enterprise value | 4.32B | 4.61B | 84.11B | 133.12B | 75.8B | |
P/E ratio | 16.14 | 23.31 | 125.17 | 66.41 | 17.04 | |
Price to sales ratio | 4.81 | 4.11 | 35.99 | 23.35 | 7.22 | |
POCF ratio | 22.71 | 17.86 | 180.99 | 79.82 | 19.53 | |
PFCF ratio | -125.27 | 44 | 1.09K | 211.7 | 25.2 | |
P/B Ratio | 3.5 | 3.12 | 33.18 | 30.06 | 6.54 | |
PTB ratio | 3.5 | 3.12 | 33.18 | 30.06 | 6.54 | |
EV to sales | 4.4 | 3.89 | 35.73 | 23.15 | 6.78 | |
Enterprise value over EBITDA | 17.09 | 14.28 | 93.26 | 52.25 | 12.98 | |
EV to operating cash flow | 20.76 | 16.9 | 179.64 | 79.15 | 18.34 | |
EV to free cash flow | -114.52 | 41.63 | 1.08K | 209.92 | 23.67 | |
Earnings yield | 0.06 | 0.04 | 0.01 | 0.02 | 0.06 | |
Free cash flow yield | -0.01 | 0.02 | 0 | 0 | 0.04 | |
Debt to equity | 0.02 | -0.06 | 0.04 | 0.06 | 0.02 | |
Debt to assets | 0.01 | -0.05 | 0.03 | 0.04 | 0.02 | |
Net debt to EBITDA | -1.6 | -0.81 | -0.7 | -0.44 | -0.84 | |
Current ratio | 2.53 | 1.8 | 2.39 | 1.96 | 3.49 | |
Interest coverage | 47.87 | 209.7 | 459.83 | 409.14 | 729.63 | |
Income quality | 0.71 | 1.3 | 0.69 | 0.81 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.02 | 0 | 0 | 0.06 | 0.03 | |
Sales general and administrative to revenue | 0.03 | 0.02 | 0.01 | 0.01 | 0 | |
Research and developement to revenue | 0.14 | 0.14 | 0.13 | 0.12 | 0.1 | |
Intangibles to total assets | 0.14 | 0.11 | 0.07 | 0.04 | 0.02 | |
Capex to operating cash flow | -1.18 | -0.59 | -0.83 | -0.62 | -0.23 | |
Capex to revenue | -0.25 | -0.14 | -0.17 | -0.18 | -0.08 | |
Capex to depreciation | -3.46 | -2.01 | -4.62 | -9.95 | -6.12 | |
Stock based compensation to revenue | 0 | 0.03 | -0.02 | 0 | 0 | |
Graham number | 2.79 | 2.46 | 5.22 | 11.58 | 40.66 | |
ROIC | 0.21 | 0.15 | 0.26 | 0.44 | 0.39 | |
Return on tangible assets | 0.19 | 0.11 | 0.21 | 0.3 | 0.3 | |
Graham Net | 0.24 | 0.08 | 0.5 | 0.84 | 7.82 | |
Working capital | 526.29M | 393.63M | 1.15B | 2.28B | 8.69B | |
Tangible asset value | 1.12B | 1.34B | 2.35B | 4.27B | 12.23B | |
Net current asset value | 426.35M | 301.47M | 1.05B | 2.16B | 8.52B | |
Invested capital | 0.02 | -0.06 | 0.04 | 0.06 | 0.02 | |
Average receivables | 210.36M | 248.23M | 517.7M | 1.55B | 3.18B | |
Average payables | 80.54M | 79.74M | 98.89M | 153.1M | 272.63M | |
Average inventory | 198.67M | 227.54M | 318.24M | 496.6M | 731.15M | |
Days sales outstanding | 78.66 | 87.79 | 116.39 | 149.44 | 130.64 | |
Days payables outstanding | 100.97 | 93.82 | 93.07 | 86.35 | 109.71 | |
Days of inventory on hand | 296.58 | 260.83 | 330.24 | 264.77 | 271.05 | |
Receivables turnover | 4.64 | 4.16 | 3.14 | 2.44 | 2.79 | |
Payables turnover | 3.61 | 3.89 | 3.92 | 4.23 | 3.33 | |
Inventory turnover | 1.23 | 1.4 | 1.11 | 1.38 | 1.35 | |
ROE | 0.22 | 0.13 | 0.27 | 0.45 | 0.38 | |
Capex per share | -0.23 | -0.15 | -0.33 | -0.85 | -1.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.98 | 2.78 | 3.2 | 1.42 | 0.64 | |
Net income per share | 1.37 | 0.87 | 1.38 | 0.51 | 0.08 | |
Operating cash flow per share | 1.37 | 0.87 | 1.38 | 0.53 | 0.58 | |
Free cash flow per share | 0.92 | 0.88 | 0.94 | 0.29 | 0.37 | |
Cash per share | 7.26 | 7.9 | 7.19 | 6.57 | 4.56 | |
Book value per share | 12.67 | 13.54 | 15.06 | 14.63 | 10.62 | |
Tangible book value per share | 12.05 | 13.42 | 14.88 | 14.17 | 10.28 | |
Share holders equity per share | 12.67 | 13.54 | 15.06 | 14.63 | 10.62 | |
Interest debt per share | 0.14 | 0.31 | 0.34 | 0.31 | 0.22 | |
Market cap | 74.49B | 82.5B | 74.84B | 60.23B | 60.12B | |
Enterprise value | 69.95B | 77.58B | 70.77B | 56.8B | 56.72B | |
P/E ratio | 14.89 | 26.04 | 15.03 | 32.92 | 141.78 | |
Price to sales ratio | 27.38 | 32.55 | 25.93 | 47.17 | 74.66 | |
POCF ratio | 59.55 | 104.17 | 60.12 | 125.54 | 82.92 | |
PFCF ratio | 88.88 | 102.38 | 87.88 | 227.17 | 129.07 | |
P/B Ratio | 6.45 | 6.68 | 5.51 | 4.56 | 4.52 | |
PTB ratio | 6.45 | 6.68 | 5.51 | 4.56 | 4.52 | |
EV to sales | 25.71 | 30.61 | 24.52 | 44.48 | 70.44 | |
Enterprise value over EBITDA | 47.86 | 90.95 | 46.82 | 114.69 | 1.58K | |
EV to operating cash flow | 55.92 | 97.96 | 56.85 | 118.38 | 78.25 | |
EV to free cash flow | 83.47 | 96.28 | 83.1 | 214.22 | 121.79 | |
Earnings yield | 0.02 | 0.01 | 0.02 | 0.01 | 0 | |
Free cash flow yield | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
Debt to equity | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
Debt to assets | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
Net debt to EBITDA | -3.11 | -5.76 | -2.69 | -6.94 | -94.29 | |
Current ratio | 3.51 | 3.49 | 3.94 | 4.14 | 3.99 | |
Interest coverage | 1.43K | 467.97 | 709.34 | 265.89 | 34.63 | |
Income quality | 1 | 1 | 1 | 1.05 | 6.84 | |
Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
Payout ratio | 0 | 0 | 0 | 1.94 | 0.18 | |
Sales general and administrative to revenue | 0.05 | -0.04 | 0.02 | -0.03 | 0.22 | |
Research and developement to revenue | 0.05 | 0.28 | 0.08 | 0.19 | 0.43 | |
Intangibles to total assets | 0.05 | 0.02 | 0.02 | 0.04 | 0.04 | |
Capex to operating cash flow | -0.33 | 0.02 | -0.32 | -0.45 | -0.36 | |
Capex to revenue | -0.15 | 0.01 | -0.14 | -0.17 | -0.32 | |
Capex to depreciation | -8.86 | 0.3 | -3.42 | -1.87 | 2.53 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Graham number | 19.78 | 16.27 | 21.62 | 12.92 | 4.5 | |
ROIC | 0.11 | 0.07 | 0.09 | 0.03 | 0.01 | |
Return on tangible assets | 0.09 | 0.05 | 0.07 | 0.03 | 0.01 | |
Graham Net | 7.35 | 7.65 | 8.22 | 7.7 | 5.06 | |
Working capital | 8.33B | 8.69B | 9.64B | 9.09B | 8.27B | |
Tangible asset value | 10.99B | 12.23B | 13.42B | 12.79B | 12.88B | |
Net current asset value | 8.17B | 8.52B | 9.44B | 8.9B | 8.06B | |
Invested capital | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
Average receivables | 4.21B | 4.13B | 4.6B | 4.98B | 4.39B | |
Average payables | 257.92M | 295.37M | 344.27M | 322.2M | 308.09M | |
Average inventory | 699.15M | 793.43M | 936.39M | 1.04B | 1.1B | |
Days sales outstanding | 140.83 | 142.15 | 162.25 | 334.5 | 451.08 | |
Days payables outstanding | 82.24 | 117.9 | 125.1 | 169.07 | 149.6 | |
Days of inventory on hand | 247.03 | 291.26 | 372.86 | 594.86 | 543.88 | |
Receivables turnover | 0.64 | 0.63 | 0.55 | 0.27 | 0.2 | |
Payables turnover | 1.09 | 0.76 | 0.72 | 0.53 | 0.6 | |
Inventory turnover | 0.36 | 0.31 | 0.24 | 0.15 | 0.17 | |
ROE | 0.11 | 0.06 | 0.09 | 0.03 | 0.01 | |
Capex per share | -0.45 | 0.02 | -0.44 | -0.24 | -0.21 |
603392.SS Frequently Asked Questions
What is Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. stock symbol ?
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a CN stock and trading under the symbol 603392.SS
What is Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. stock quote today ?
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. stock price is $69.44 today.
Is Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. stock public?
Yes, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a publicly traded company.